Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Shares Bought by Fairbanks Capital Management Inc.

Fairbanks Capital Management Inc. raised its stake in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) by 4.5% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 27,112 shares of the specialty pharmaceutical company’s stock after buying an additional 1,178 shares during the quarter. Jazz Pharmaceuticals comprises about 1.9% of Fairbanks Capital Management Inc.’s portfolio, making the stock its 18th biggest holding. Fairbanks Capital Management Inc.’s holdings in Jazz Pharmaceuticals were worth $2,894,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors also recently bought and sold shares of the company. Rise Advisors LLC increased its stake in Jazz Pharmaceuticals by 2,255.6% during the first quarter. Rise Advisors LLC now owns 212 shares of the specialty pharmaceutical company’s stock worth $26,000 after purchasing an additional 203 shares during the period. Versant Capital Management Inc increased its stake in Jazz Pharmaceuticals by 13,450.0% during the second quarter. Versant Capital Management Inc now owns 271 shares of the specialty pharmaceutical company’s stock worth $29,000 after purchasing an additional 269 shares during the period. GAMMA Investing LLC increased its stake in Jazz Pharmaceuticals by 65.5% during the second quarter. GAMMA Investing LLC now owns 293 shares of the specialty pharmaceutical company’s stock worth $31,000 after purchasing an additional 116 shares during the period. Gladius Capital Management LP purchased a new stake in Jazz Pharmaceuticals during the second quarter worth about $33,000. Finally, Cape Investment Advisory Inc. increased its stake in Jazz Pharmaceuticals by 14,600.0% during the fourth quarter. Cape Investment Advisory Inc. now owns 294 shares of the specialty pharmaceutical company’s stock worth $36,000 after purchasing an additional 292 shares during the period. Institutional investors and hedge funds own 89.14% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages have issued reports on JAZZ. Cantor Fitzgerald reiterated an “overweight” rating and set a $140.00 price target on shares of Jazz Pharmaceuticals in a research note on Thursday, August 1st. Needham & Company LLC cut their price target on shares of Jazz Pharmaceuticals from $208.00 to $205.00 and set a “buy” rating on the stock in a research note on Thursday, August 1st. HC Wainwright reiterated a “buy” rating and set a $200.00 price target on shares of Jazz Pharmaceuticals in a research note on Thursday, August 1st. UBS Group cut their target price on shares of Jazz Pharmaceuticals from $117.00 to $113.00 and set a “neutral” rating on the stock in a research note on Tuesday, July 2nd. Finally, Morgan Stanley cut their target price on shares of Jazz Pharmaceuticals from $160.00 to $150.00 and set an “equal weight” rating on the stock in a research note on Friday, July 12th. Four equities research analysts have rated the stock with a hold rating, eleven have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $173.07.

Jazz Pharmaceuticals Stock Performance

Shares of Jazz Pharmaceuticals stock opened at $107.14 on Monday. The firm has a market capitalization of $6.62 billion, a P/E ratio of 22.09, a P/E/G ratio of 1.34 and a beta of 0.57. Jazz Pharmaceuticals plc has a 52 week low of $99.06 and a 52 week high of $137.57. The company has a quick ratio of 2.02, a current ratio of 2.37 and a debt-to-equity ratio of 1.36. The firm’s 50 day moving average is $109.75 and its two-hundred day moving average is $112.12.

Jazz Pharmaceuticals Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.